Shares of Gilead Sciences declined by 1.38% in the most recent trading session, underperforming the broader market’s modest gains. The stock’s 50-day moving average stands at $122.99 while the 200-day moving average is $116.80, reflecting a recent uptrend that has encountered profit-taking pressure. Trading volume was roughly in line with the 30-day average, indicating investor caution but no extreme volatility.

Abacus FCF Advisors reduced its position in Gilead Sciences by 16.0% during the third quarter, selling 26,340 shares and ending the period with 138,674 shares valued at $15.39 million, accounting for 2.0% of the firm’s portfolio. On the buy side, Norges Bank initiated a new stake worth $2.15 billion in the second quarter, and Ameriprise Financial boosted its holdings by 397.6%, adding 5.39 million shares. Insider activity was skewed to selling: Johanna Mercier disposed of 3,000 shares for roughly $366,000 and Director Jeffrey Bluestone sold 5,000 shares for about $625,400, reducing their ownership by 2.75% and 35.92%, respectively.

In the third quarter, Gilead reported adjusted earnings per share of $2.47, beating consensus by $0.31, on revenue of $7.77 billion, 3.0% above year-ago levels and $350 million ahead of estimates. The company delivered a net margin of 27.9% and a return on equity of 51.9%. Management set full-year 2025 EPS guidance in a range of 8.05 to 8.25, compared with the street’s forecast of 7.95. Key balance sheet metrics include a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45.

Gilead declared a quarterly dividend of $0.79 per share, payable December 30, yielding 2.5% on an annualized basis and representing a 48.99% payout ratio. Eleven brokerages have raised price targets in recent weeks, including Morgan Stanley (to $151) and Wells Fargo (to $150), while Mizuho and Argus have maintained Outperform and Buy ratings with targets of $140 and $135, respectively. The consensus among 28 analysts is a Moderate Buy, with an average target of $131.68.